大型医院队列中I期子宫内膜癌辅助放疗的使用模式与生存结局
基于美国国家癌症数据库(NCDB)分析2004至2011年间61,697例I期子宫内膜腺癌患者,83.9%未接受辅助放疗;辅助放疗使用随分期/分级升高而增加,多因素分析显示外照射放疗(HR 0.83)和近距离放疗(HR 0.82)均与IB期患者生存改善相关,倾向匹配队列中放疗与生存改善相关(HR 0.85)。
要点
- I期子宫内膜癌患者中83.9%未接受辅助放疗,放疗使用随分期/分级升高而增加。
- IB期患者中,辅助外照射放疗(HR 0.83)和近距离放疗(HR 0.82)均与生存改善相关。
- 倾向匹配队列中,辅助放疗与生存改善相关(HR 0.85,95%CI 0.78-0.92,p<0.001)。
核心结论
- I期子宫内膜癌辅助放疗的使用高度取决于分期/分级,且与IB期患者生存改善相关。
研究设计与样本
- 基于美国国家癌症数据库(NCDB)的队列分析,纳入2004至2011年间行全子宫切除/双侧输卵管卵巢切除术的AJCC pT1N0M0期子宫内膜腺癌患者,排除生存<4个月者,共61,697例。
主要发现
- 83.9%的患者未接受辅助放疗;辅助放疗使用随分期/分级升高而增加。
- 近距离放疗单独使用从IA/G1的78.2%降至IB/G3的36.1%,外照射放疗从IA/G1的21.8%升至IB/G3的53.9%。
- 多因素分析中,IB期患者辅助外照射放疗(HR 0.83,95%CI 0.74-0.93,p=0.002)和近距离放疗(HR 0.82,95%CI 0.74-0.93,p=0.002)均与生存改善相关。
- 倾向匹配队列中,放疗与生存改善相关(HR 0.85,95%CI 0.78-0.92,p<0.001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Two randomized trials have demonstrated a local control advantage in the absence of a survival advantage for the addition of adjuvant radiation therapy (RT) to surgery in patients with stage I endometrial adenocarcinoma (EC). This study analyzed the National Cancer Data Base (NCDB) to evaluate the impact of adjuvant RT on overall survival (OS) for patients with stage I EC. METHODS: Patients with EC who underwent total hysterectomy/bilateral salpingo-oophorectomy between 2004 and 2011 were queried. Only those with AJCC stage pT1N0M0 were included. Patients surviving <4months excluded. Adjuvant RT included external beam RT (EBRT), brachytherapy, or external RT+brachytherapy. OS was analyzed using the Kaplan-Meier method. Multivariate Cox regression analysis and propensity matched analysis were performed to assess the impact of covariates on OS. RESULTS: There were 61,697 patients included. Most women (83.9%) did not receive adjuvant RT. Adjuvant RT usage increased with increasing stage/grade. Usage of brachytherapy alone decreased with increasing stage/grade (78.2% for IA/G1 to 36.1% for IB/G3) corresponding to an increase in the use of EBRT (21.8% for IA/G1 to 53.9% for IB/G3). On multivariable analysis, adjuvant EBRT (HR 0.83, 95%CI 0.74-0.93, p=0.002) and brachytherapy (HR 0.82, 95%CI 0.74-0.93, p=0.002) were each associated with improved survival for women with stage IB. In the propensity matched cohort, RT was associated with improved survival (0.85, 95% CI 0.78-0.92, p<0.001). CONCLUSION: The use of adjuvant RT for women with stage I EC is highly dependent on stage/grade and is associated with improved survival for stage IB.
引用
- Wong AT, Rineer J, Schwartz D, et al. Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort. Gynecol Oncol. 2016. PMID: 27823769. doi:10.1016/j.ygyno.2016.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。